Form 4: Pacira BioSciences Director Equity Grant Disclosure
Statement of Changes in Beneficial Ownership
Director Alethia Young received a grant of restricted stock units and stock options as part of standard compensation.
Summary
- Director Alethia Young was granted 6,405 restricted stock units (RSUs) on June 10, 2026.
- Director Alethia Young was granted 10,891 stock options with an exercise price of $23.42 on June 10, 2026.
- Both the RSUs and stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
- Following these transactions, the director's total direct beneficial ownership of common stock increased to 17,798 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standardized compensation structure for board members.
Negatives
- Minor dilution to existing shareholders resulting from the issuance of new equity awards.
Risks
- Vesting is contingent upon the director remaining in continuous service with the issuer through June 10, 2027.
Future Outlook
The equity awards are subject to continued service requirements, with full vesting scheduled for June 10, 2027.
Management Comments
- The filing does not contain narrative management commentary.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, which is standard practice for publicly traded biotechnology companies to incentivize board oversight and long-term strategic alignment.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. biotech sector.
- The grant size is typical for non-employee director compensation packages among mid-cap pharmaceutical firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to a director. | 06/10/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minimal impact on shareholders due to the standard nature of director compensation.
Next Steps
- Vesting of equity awards on June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of the equity grant transaction. |
| 06/10/2027 | Vesting date for both RSUs and stock options. |
| 06/10/2036 | Expiration date for the granted stock options. |
| 06/12/2026 | Date of filing. |
Keywords
Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.